No Data
No Data
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
Express News | Immunoprecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
Express News | Immunoprecise Antibodies Successfully Engineers in Silico Antibodies to Elusive Tumor Protein Using Its Patented Lensai Technology
Benchmark Co. Maintains ImmunoPrecise Antibodies(IPA.US) With Buy Rating, Cuts Target Price to $3
Express News | Benchmark Maintains Speculative Buy on ImmunoPrecise Antibodies, Lowers Price Target to $3
Express News | Immunoprecise Antibodies Ltd : Benchmark Cuts Target Price to $3
No Data